Renal Association Clinical Practice Guideline on Prevention of Blood Borne Virus Infection in the Renal Unit

Geddes, Colin C.; Lindley, Elizabeth; Duncan, Neill

doi:10.1159/000328068

Cited by 11 publications

(11 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the British guidelines strongly recommend that dialysis patients receive a double and frequent dose schedule (Fendrix 20 mg at 0, 1, 2, and 6 months; Engerix‐B 40 mg at 0, 1, 2, and 6 months; or HBvaxPRO 40 mg at 0, 1, and 6 months) with booster doses if the annual anti‐HBs titer is <100 mIU/mL. Nonresponders to this schedule should receive no further immunization with currently available preparations . The US recommendations are almost identical…”

Section: Hepatitis Bmentioning

confidence: 99%

Vaccination practices in dialysis patients: A narrative review

Kosmadakis

Albaret

Correia

et al. 2018

Seminars in Dialysis

View full text Add to dashboard Cite

In a period of turmoil concerning vaccination practices, there is a serious conflict between scientifically reasonable, evidence-based guidelines and the far-fetched rumors or misconceptions concerning the vaccination practices in the general population. When a significant portion of the medical and paramedical personnel may be deliberately unvaccinated against common biological agents, achieving effective vaccination rates in the dialysis population may be complicated. Vaccination rates are unacceptably low in dialysis patients and seroconversion rates are even lower; further, serological follow-up is generally poor. The particularly anergic immune system of the advanced chronic kidney disease patients is partly a cause of both high rates of infection and low rates of seroconversions. This narrative review is an effort to summarize current knowledge concerning the vaccination practices in dialysis patients with some specific recommendations based on these facts. Of particular interest is a new vaccine, the Zoster Recombinant, Adjuvanted Vaccine (Shingrix), which we will include in our discussion.

show abstract

Section: Hepatitis Bmentioning

confidence: 99%

Vaccination practices in dialysis patients: A narrative review

Kosmadakis

Albaret

Correia

et al. 2018

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

“…The use of a second transducer protector in series with the standard ones on the blood lines for patients who are HCV-positive (as described in the rationale to guideline 2.4 of ref. 4 and shown in Figure 1 ) is the ideal measure for eliminating the risk of transmission via the pressure ports. As the use of double transducer protectors means that HCV-positive patients can share machines with uninfected patients, they can dialyse in any unit and on any shift, and patients who have hepatitis B immunity do not require named machines when returning from holidays in high-risk areas.…”

Section: Alternative Transmission Routesmentioning

confidence: 99%

“…As Thomson et al points out, this recommendation goes beyond the current guidance provided by Kidney Disease: Improving Global Outcomes (KDIGO), [ 2 ], European Renal Best Practice [ 3 ] and the UK Renal Association [ 4 ]. None of these bodies advocate the use of dedicated machines.…”

Section: Introductionmentioning

confidence: 99%

How plausible is transmission of hepatitis C virus via the haemodialysis circuit?

Lindley

Boyle

Gandy

et al. 2011

Clinical Kidney Journal

View full text Add to dashboard Cite

“…Furthermore, due to the uraemia-associated immune dysfunction, HD patients are also more likely to become chronic carriers once infected 2. The key principles of HBV infection control in dialysis units include screening of all HD patients, segregation of those who are infectious and vaccination of susceptible individuals 3. The widespread implementation of these measures has led to a dramatic decline in the incidence of HBV infection in dialysis patients over the past decades; however, sporadic outbreaks continue to occur even in developed countries, due to breaches in infection control procedures and suboptimal immunisation of susceptible individuals 4…”

Section: Introductionmentioning

confidence: 99%

Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster

et al. 2014

View full text Add to dashboard Cite

SUMMARYPatients receiving haemodialysis are at an increased risk of hepatitis B infection; regular screening for incident infection and vaccination of susceptible individuals is recommended. Haemodialysis patients often require repeated high-dose hepatitis B vaccination boosters because of impaired response. Since the hepatitis B surface antigen is used as an immunogenic agent for vaccination and as a marker of hepatitis B infection, it has occasionally been detected in the blood shortly after vaccine administration and can be mistaken for a new infection. These transient results, however, are unlikely to persist for longer than 14 days after vaccination. We report the case of a haemodialysis patient who tested weakly positive for hepatitis B surface antigen 52 days after a vaccine booster. This is the longest vaccineinduced antigenaemia described in the literature and indicates that vaccination can cause weakly positive hepatitis B surface antigen results for longer than previously reported. BACKGROUND

show abstract

Renal Association Clinical Practice Guideline on Prevention of Blood Borne Virus Infection in the Renal Unit

Cited by 11 publications

References 81 publications

Vaccination practices in dialysis patients: A narrative review

Vaccination practices in dialysis patients: A narrative review

How plausible is transmission of hepatitis C virus via the haemodialysis circuit?

Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster

Contact Info

Product

Resources

About